randomized controlled

Related by string. Randomized controlled * Randomized : randomized controlled trial / controlling : obtaining controlled substance * randomized controlled trials . randomized controlled clinical trials . randomized controlled trials RCTs . randomized controlled clinical . prospective randomized controlled . blind randomized controlled . Randomized Controlled Trial *

Related by context. All words. (Click for frequent words.) 83 randomized placebo controlled 83 prospective randomized 83 randomized clinical 81 placebo controlled 80 multicenter 79 randomized controlled trial 79 randomized double 77 randomized 77 multicenter randomized 76 double blind placebo 76 randomized multicenter 75 randomized controlled clinical 75 blind randomized 75 multicentre 75 prospective randomized controlled 75 blind randomized placebo 74 Phase III randomized 74 placebo controlled randomized 73 multicenter randomized double 73 double blinded randomized 72 blind placebo controlled 71 nonrandomized 71 placebo controlled clinical 71 multicenter study 71 multicentre randomized 70 prospective multicenter 70 randomized controlled trials 70 randomized Phase III 70 blinded placebo controlled 70 multicenter clinical 70 randomized clinical trials 69 prospective observational 69 placebo controlled Phase 69 multicentre randomized double 69 label multicenter 69 randomized trials 69 blind multicenter 69 masked placebo controlled 69 controlled multicenter 68 placebo controlled studies 68 clinical trial 68 multicenter randomized placebo controlled 68 multicenter prospective 67 observational study 67 placebo controlled trials 67 multicenter randomized controlled 67 multicentre study 67 blind randomized controlled 66 Phase 2b study 66 double blinded placebo 66 dose escalation trial 66 placebo controlled Phase III 66 randomized blinded 66 blinded randomized 65 active comparator 65 dose escalation study 65 randomized controlled clinical trials 65 prospective randomized multicenter 65 multicenter Phase II 65 label dose escalation 65 randomized multicenter trial 64 Phase III clinical 64 prospective multicenter randomized 64 prospective cohort 64 Phase 1b clinical 64 dose escalation Phase 64 phase IIb clinical 64 Phase 2a clinical 64 phase IIIb 64 multicenter placebo controlled 64 Phase IIb trial 64 Phase IIIb 64 randomized Phase IIb 64 prospective randomized placebo 63 blind placebo 63 dose dose escalation 63 phase IIa clinical 63 multicenter randomized clinical 63 randomized multicentre 63 dose escalation clinical 63 randomized crossover 63 RE LY ® 63 randomized Phase 63 trials RCTs 62 TMC# C# 62 multicenter multinational 62 dose escalation 62 phase IIa 62 phase IIb 62 multicenter Phase III 62 subanalysis 62 pivotal Phase III 62 substudy 62 blinded randomized controlled 62 phase Ib 62 Phase 2b clinical 62 pivotal Phase 62 single ascending dose 61 REALITY Trial 61 ascending dose 61 label multicenter Phase 61 Phase Ia 61 Phase IIb 61 ONTARGET 61 NO# [002] 61 non inferiority 61 placebo controlled dose escalation 61 Phase 2a trial 61 meta analysis 61 Phase IIa 61 Randomized controlled 61 Phase Ib clinical 61 multicenter Phase 61 Phase 2b trial 61 noninferiority 61 PRECiSE 61 randomized #:# 61 Randomized 61 phase 2a 61 label multicenter randomized 61 RE LY 61 landmark ATHENA 60 nab paclitaxel 60 Phase III 60 prospective nonrandomized 60 Phase Ib 60 TAXUS ATLAS 60 HCV SPRINT 60 dabigatran etexilate 60 Phase 1b trial 60 Phase 1b 60 TG MV 60 AIR CF3 60 Phase #/#a 60 ADVANCE PD 60 Sorafenib HCC Assessment 60 Phase IIIb study 60 LUX Lung 60 NCT# ClinicalTrials.gov 60 blind multicentre 59 Phase IIa trial 59 Phase IIb clinical 59 Phase III pivotal 59 Randomised 59 prospectively randomized 59 viral kinetic 59 observational studies 59 subgroup analyzes 59 pharmacokinetics PK 59 ExTRACT TIMI 59 randomized controlled Phase 59 AIR CF2 59 Carotid Revascularization Endarterectomy vs. 59 EVEREST II 59 EchoCRT 59 symptomatic BPH 59 ASCEND HF 59 SPIRIT III 59 DAPT 59 BRIM2 59 HPTN 59 Phase IIIb clinical 59 blinded randomized placebo controlled 59 Phase III placebo controlled 59 Phase 2a 59 safety tolerability pharmacokinetics 59 longitudinal cohort study 58 Phase 1a 58 Randomized Evaluation 58 BRIM3 58 multiple ascending dose 58 unblinding 58 RCTs 58 PFO migraine 58 Stenting Trial CREST 58 ENDEAVOR IV 58 ABSORB trial 58 tolerability 58 phase IIb trial 58 multicenter trials 58 COMFORT II 58 label dose titration 58 multicenter phase 58 prospective multicentre 58 retrospective cohort study 58 Phase 2b 58 SPIRIT IV 58 AIR CF1 58 EURIDIS 58 Multicenter 58 VICTOR E1 57 dose regimens 57 Betaferon ® 57 RSD# oral 57 EDEMA3 57 unblinded 57 phase IIb study 57 patients undergoing percutaneous 57 treatment naive genotype 57 randomized controlled multicenter 57 placebo controlled clinical trials 57 randomized multicenter Phase III 57 clinical trials 57 Phase IIa clinical 57 monotherapy 57 observer blinded randomized 57 Phase Ib II 57 multicentre prospective 57 confirmatory clinical 57 SPIRIT FIRST 57 ECASS 57 NOXAFIL Oral Suspension 57 ANCHOR trial 57 RG# ITMN 57 AVERROES 57 post hoc 57 multicentre randomized controlled 57 dose titration 57 oral rivaroxaban 57 pivotal bioequivalence 57 efficacy 57 TRITON TIMI 57 Placebo controlled 57 Phase III trials 57 CLL8 57 APPRAISE 57 Phase 2b randomized 57 NATRECOR ® 57 VADT 57 riociguat 56 MADIT II 56 ROCKET AF 56 Clinical Antipsychotic Trials 56 Phase IIB 56 sunitinib malate 56 chemoradiotherapy 56 blind randomized multicenter 56 IMPROVE IT 56 metastatic HRPC 56 Prostate Lung Colorectal 56 LITHE 56 comparing XIENCE V 56 treatment naïve genotype 56 HCV RESPOND 2 56 DAPT Study 56 telmisartan 56 PRECISE 56 ASTEROID 56 registrational Phase 56 pegylated interferon alfa 2b 56 confirmatory Phase III 56 vicriviroc 56 acute ischemic stroke 56 LibiGel Phase III 56 HORIZONS AMI trial 56 analgesic efficacy 56 AIM HIGH 56 Intervention Effectiveness 56 ABSORB clinical 56 retrospective observational study 56 GEM OS1 56 #:# randomization 56 MIST II 56 controlled dose escalation 56 VITAL Trial 56 STRIDE PD 56 bronchial thermoplasty 56 prospectively defined 56 primary endpoint 56 dose escalation phase 56 RoACTEMRA 56 #mg/day [001] 56 ascending doses 56 Val HeFT 56 Initiated Phase 56 MEND CABG 56 meta analyzes 56 CALGB 56 Phase 2b kidney transplant 56 randomized #:#:# 56 teriflunomide 56 ALLHAT 56 CHAMPION PCI 56 MERLIN TIMI 56 GOUT 56 European Sepsis Trial 56 multinational multicenter randomized 56 PREZISTA r 56 CIMZIA TM certolizumab pegol 56 PRoFESS 55 Phase III randomized controlled 55 safety tolerability 55 APTIVUS 55 placebo controlled multicenter 55 BARI 2D 55 observational cohort 55 PRE SURGE 55 NICE SUGAR 55 Phase III multicenter 55 TAXUS VI 55 factorial design 55 ToGA 55 rosuvastatin 55 AVADO 55 Phase Ib study 55 CLARITY study 55 ACTEMRA 55 ATTRACT 55 IMPROVE HF 55 neoadjuvant 55 TAXUS IV 55 phase Ib clinical 55 CARE HF 55 eculizumab 55 KRN# 55 GetGoal Phase III 55 pharmacokinetic PK 55 Multi Ethnic Study 55 Prostate Cancer Prevention 55 RRMS patients 55 clinical pharmacology studies 55 eptifibatide 55 pharmacodynamics 55 controlled multicenter Phase 55 primary hypercholesterolemia 55 postmenopausal women 55 retrospective cohort 55 viral kinetics 55 phase III ACCLAIM 55 composite endpoint 55 NSABP B 55 paclitaxel eluting stents 55 Phase #b/#a 55 carotid artery stenting 55 randomized Phase 2b 55 evaluating tivozanib 55 ACTIVE W 55 oral deforolimus 55 PREVAIL 55 randomized blinded placebo 55 observational cohort study 55 ENESTnd 55 dosing regimens 55 recurrent malignant glioma 55 evaluating REVLIMID 55 bendamustine 55 sunitinib 55 BR.# 55 elective PCI 55 APEX PD 55 LEXIVA r 55 sequential dose escalation 55 ARIXTRA 55 everolimus eluting stents 55 pharmacodynamics PD 55 glatiramer acetate 55 Pivotal Trial 55 mg dose 55 AIR2 Trial 55 sorafenib Nexavar 55 sirolimus eluting stent 55 NCCTG 55 irbesartan 55 Prospective Randomized 55 Phase Ib clinical trials 54 ILLUMINATE 54 NEVO RES 54 e HEALING 54 bosentan 54 everolimus eluting stent 54 pegylated liposomal doxorubicin 54 pertuzumab 54 HOPE TOO 54 neratinib 54 lixisenatide 54 recurrent glioblastoma multiforme 54 RE MODEL 54 ACTEMRA TM 54 APTIVUS r 54 dosage regimens 54 Cholesterol Levels SPARCL 54 Edge STudy 54 dose cohorts 54 ACUITY trial 54 MADIT CRT 54 pain palliation 54 Phase III VISTA 54 pharmacokinetic 54 XIENCE V Stent System 54 desvenlafaxine succinate 54 safety tolerability pharmacokinetic 54 Myocardial Infarction Study 54 Phase III metastatic melanoma 54 Phase IIb III 54 DU #b 54 CATIE AD 54 relapsing multiple sclerosis 54 tocilizumab 54 CURRENT OASIS 7 54 HeFT 54 Intervention Trial GAIT 54 peginterferon alfa 2b 54 GAMMAGARD 54 anti arrhythmic drug 54 Randomized Phase 54 PRIMO CABG 54 efficacy endpoints 54 oral ridaforolimus 54 prospective longitudinal 54 CYPHER Stent 54 AEGR 54 FOLFOX 54 Capesaris 54 cetrorelix 54 darunavir ritonavir 54 TRANSFORMS 54 ongoing Phase 1b 54 DSMB 54 Thrombolysis 54 adalimumab 54 blinded placebo 54 posaconazole 54 registrational trial 54 tolerability pharmacokinetics 54 UKPDS 54 superficial bladder cancer 54 Raloxifene Evaluation MORE 54 temsirolimus 54 CANCIDAS 54 dosing cohorts 54 evaluable patients 54 rALLy clinical trial 54 ritonavir boosted 54 CYPHER ® Stent 54 DURATION 54 Heart Failure Trial 54 SWOG 54 Communities ARIC study 54 secondary efficacy endpoints 54 pramlintide 54 lubiprostone 54 CAMMS# 54 icatibant 54 ticagrelor 54 iniparib 54 cilostazol 54 valsartan 54 eprotirome 54 noninferior 54 recurrent GBM 54 NEVO ™ 54 pazopanib 54 thorough QT 54 Amrubicin 54 dyskinesia PD LID 53 BCIRG 53 registrational 53 bevacizumab Avastin 53 colesevelam HCl 53 #mg QD [002] 53 EOquin TM 53 Phase 1a clinical 53 CYPHER R Sirolimus eluting 53 Intervention Trial 53 docetaxel chemotherapy 53 prespecified 53 Augment Injectable 53 efficacy tolerability 53 refractory CLL 53 mg QD 53 abatacept 53 cluster randomized controlled 53 opioid induced bowel dysfunction 53 RE LY trial 53 rt PA 53 tolvaptan 53 HYVET 53 SYNTAX trial 53 Phase #b/#a trial 53 Dacogen injection 53 pharmacokinetic studies 53 OLYMPIA registry 53 Degarelix 53 ascending dose study 53 ZYBRESTAT fosbretabulin 53 Traficet EN 53 bevacizumab 53 CLBP 53 transcatheter aortic valve implantation 53 velafermin 53 lanthanum carbonate 53 Acute Ischemic Stroke 53 NLX P# 53 clazosentan 53 Phase IIa trials 53 SYNTAX 53 SIMPADICO 53 rFVIIa 53 cinacalcet 53 NATRECOR R 53 REVLIMID lenalidomide 53 doxorubicin docetaxel 53 HORIZONS AMI 53 liver transplant recipients 53 Aggressive Reduction 53 GISSI HF 53 pharmacodynamic effects 53 plus dexamethasone 53 paclitaxel eluting stent 53 International Verapamil SR 53 subcutaneous methylnaltrexone 53 CoFactor 53 ADAGIO study 53 HF ACTION 53 ataluren 53 Phase III clinical trials 53 sirolimus eluting stents 53 Stenting Trial 53 comparator arm 53 Phase Ib IIa clinical 53 EmbraceAC 53 CALGB # [001] 53 RIO Lipids 53 CYPHER R Stent 53 satraplatin Phase 53 risperidone Risperdal 53 Study ADX# 53 mixed hyperlipidemia 53 NOXAFIL 53 daily Infergen 53 fenretinide 53 tiotropium 53 Endovascular Valve Edge 53 LCP AtorFen 53 RE SURGE 53 reslizumab 53 Screening Trial 53 fostamatinib 53 LEVADEX 53 Protelos 53 RESOLUTE 53 UPLIFT 53 REVIVE Diabetes 53 tesofensine 53 de novo kidney transplant 53 Trandolapril 53 pharmacokinetic PK study 53 pharmacodynamic profile 53 pharmacokinetic pharmacodynamic 53 mg administered orally 53 sipuleucel T 53 oral Xeloda 53 MADIT 53 relapsing remitting multiple sclerosis 53 AVOREN 53 paricalcitol 53 pomalidomide 53 assessing T DM1 53 SPARCL 53 Torisel 53 NGX# 53 Rosuvastatin 53 IIa trial 53 insulin detemir 53 Multicentre 53 BOLDER II 53 Clinical Outcomes Utilizing Revascularization 53 unfractionated heparin UFH 53 Atherosclerosis MESA 53 CA4P 52 eluting stent 52 bivalirudin 52 ENDEAVOR II 52 ENDEAVOR clinical 52 PROMUS Element Stent 52 Cloretazine 52 TAXUS V 52 Rheos System 52 Phase II 52 Phase III Clinical Trial 52 LPV r 52 NCT# 52 pharmacodynamic PD 52 relapsed myeloma 52 efficacy endpoint 52 RECORD1 52 ZACTIMA 52 ORMD 52 investigational drug 52 EFAPROXYN 52 lintuzumab 52 XL# SAR# 52 sirolimus eluting 52 ABCSG 52 primary efficacy endpoint 52 prospective observational cohort 52 NSTE ACS 52 RezularTM 52 CALGB # [002] 52 subcutaneously administered 52 Phase III randomized placebo 52 tanespimycin 52 interferon beta 1b 52 SCH # 52 CTA# Injection 52 clinically meaningful 52 mycophenolate mofetil 52 HCV infected 52 EORTC 52 dose regimen 52 MAGE A3 ASCI 52 Acute Myocardial Infarction 52 Ophena TM 52 carotid stenting 52 canakinumab 52 bicifadine 52 CAPRISA 52 mg doses 52 trastuzumab emtansine T DM1 52 relapsed refractory multiple myeloma 52 BOLDER 52 recurrent ovarian cancer 52 secondary endpoint 52 ATACAND 52 plus ribavirin 52 Radiation Therapy Oncology 52 hypertensive patients 52 CYPHER R stent 52 null responder HCV 52 eosinophilic asthma 52 HuMax EGFr 52 Phase III Pivotal 52 PFO closure 52 prospective multicenter study 52 STICH trial 52 oral diclofenac 52 ZoMaxx 52 Aggressive Drug Evaluation 52 CYPHER ® Sirolimus eluting 52 mg BID 52 Prostate AdenoCarcinoma Treatment 52 undergoing elective percutaneous 52 eplerenone 52 designated HVTN 52 unstable angina UA 52 afatinib 52 protease inhibitor PI 52 COU AA 52 allopurinol 52 pioglitazone 52 lipid lowering 52 QD dosing 52 rNAPc2 52 crizotinib PF # 52 standard chemotherapy regimen 52 hypogonadal men 52 diabetic neuropathic pain 52 XIENCE V demonstrated 52 Adlea 52 Cochrane Systematic Review 52 axitinib 52 secondary endpoints 52 PROPEL trial 52 lipid lowering therapy 52 intravitreal injection 52 HIVNET 52 retinal vein occlusion induced 52 AEG# 52 TORISEL 52 EVIZON 52 Dabigatran 52 CUSTOM II 52 strontium ranelate 52 NSABP C 52 candesartan cilexetil 52 Tolvaptan 52 IMPACT DCM 52 degarelix 52 multicenter randomized Phase 52 Taxotere ® 52 eltrombopag 52 DCCT 52 ARDIS 52 relapsed MM 52 levosimendan 52 irinotecan chemotherapy 52 galiximab 52 landmark ATHENA study 52 APEX AMI trial 52 boosted protease inhibitor 52 relapsing remitting MS 52 CLARITY TIMI 52 Scandinavian Simvastatin Survival 52 investigational oral 52 urate lowering 52 ConclusionThis 52 biologic therapy 52 basal bolus regimen 52 rivaroxaban 52 eszopiclone 52 ACCORD Lipid 52 ACCORD 52 ancrod 52 low dose cytarabine 52 KAPIDEX 52 morphometric vertebral fractures 52 bupropion SR 52 azacitidine 52 Randomized Clinical Trial 52 Edwards SAPIEN valve 52 olopatadine 52 INCB# [001] 52 fosbretabulin 52 Cardiac Allograft Rejection 52 Board DSMB 52 tipranavir 52 primary endpoints 51 CORD II 51 tremelimumab 51 ENDEAVOR 51 MADIT CRT trial 51 ELCAP 51 FOSRENOL R 51 CRx 51 candesartan 51 PROMACTA 51 TMC# r 51 edoxaban 51 BoNTA 51 ONGLYZA 51 placebo 51 Combo Stent 51 SCD HeFT 51 SUCCEED trial 51 pimecrolimus cream 51 BETAS 51 IFN alfa 51 Val MARC 51 aflibercept 51 evaluating Actimmune 51 chronic angina 51 Phenoptin 51 Clinical trials 51 statin therapy 51 Tocilizumab 51 intravenous methylnaltrexone 51 fondaparinux 51 Phase 1b dose escalation 51 longitudinal study 51 tapentadol ER 51 hemodialysis patients 51 multidose 51 antiepileptic drug 51 HZT 51 fluvastatin 51 ENVISION 51 MEND CABG II 51 Ophena 51 CERVARIX 51 Ovarian Cancer Screening 51 CIMZIA ™ 51 pitavastatin 51 bevacizumab Avastin ® 51 tolerability profile 51 sulodexide 51 nesiritide 51 PREVENT IV 51 PD LID 51 NCCTG N# 51 ofatumumab 51 PEGINTRON TM 51 severe aortic stenosis 51 mcg dose 51 Health Initiative WHI 51 EQUIP OB 51 Proellex TM 51 Diabetic Macular Edema 51 Phase 2b clinical trials 51 Telmisartan 51 sorafenib Nexavar ® 51 mg RDEA# 51 alvimopan 51 randomly assigned 51 ZYBRESTAT 51 tecarfarin 51 dose cohort 51 Endeavor Resolute DES 51 arzoxifene 51 lacosamide 51 antihypertensive therapy 51 ELONVA 51 phase III SIMPADICO 51 μg dose 51 PICSO ® 51 EDEMA4 51 Randomized Placebo Controlled 51 Imprime PGG 51 rilonacept 51 dose pharmacokinetic 51 dose placebo controlled 51 pegylated interferon alfa 2a 51 zotarolimus eluting stent 51 Ovarian PLCO Cancer 51 Microplasmin 51 PRX # 51 SORT OUT III 51 bolus dose 51 Ranolazine 51 oral anticoagulant 51 ganetespib 51 RAPAFLO R 51 dosing cohort 51 inhibitor RG# 51 CRESTOR #mg 51 Intervention Effectiveness CATIE 51 forodesine 51 Pivotal Phase 51 MIVI TRUST 51 pharmacodynamic 51 number NCT# ClinicalTrials.gov 51 Phase III psoriasis 51 subcutaneous formulation 51 trodusquemine 51 STEALTH C 51 Phase Ib IIa 51 achieved statistical significance 51 JANUVIA 51 Left Ventricular Dysfunction 51 budesonide foam 51 TAXUS stent 51 Xelox 51 premenopausal women 51 DASISION 51 BRAF inhibitor 51 adecatumumab 51 mg/m2 dose 51 Phase IIA 51 clopidogrel Plavix 51 angiotensin receptor blocker ARB 51 pre menopausal 51 VIRAMUNE XR 51 ACCOMPLISH 51 SCIg 51 NP2 Enkephalin 51 fistulizing Crohn disease 51 Adalimumab 51 NEVO 51 carotid artery stenting CAS 51 ruboxistaurin 51 ginkgo extract 51 brivaracetam 51 5-FU/LV 51 efavirenz EFV 51 Navelbine 51 CHAMPION PLATFORM 51 Zilver PTX 51 PEG INTRON R 51 MIRCERA 51 adjunctive placebo 51 fenofibric acid 51 FOLFIRI 51 II Clinical Trial 51 patients undergoing CABG 51 mixed dyslipidemia 51 anti arrhythmic 51 enzastaurin 51 fallopian tube cancers 51 salmeterol fluticasone 51 lomitapide 51 radical cystectomy 51 cangrelor 51 GORE VIABAHN Endoprosthesis 51 PCI ExTRACT TIMI 51 Group RTOG 51 iPrEx 51 metreleptin 51 epidemiologic studies 51 safinamide 51 OPT CHF 51 aliskiren 51 acute coronary syndromes ACS 51 LUMINATE 51 deferiprone 51 EINSTEIN DVT 51 randomized discontinuation trial 51 NSABP 51 Multiethnic Study 51 telaprevir dosed 51 Clinical Study 51 ENGAGE AF TIMI 51 nulliparous women 51 adjuvant colon cancer 51 ocular hypertension 51 Dialysis Outcomes 51 Endarterectomy 51 CombAT 51 patients evaluable 51 denufosol 51 6R BH4 51 Betaferon R 51 elagolix 51 TAXUS Liberte Stent 51 TOLAMBA 51 ADMIRE HF 51 EGS# 51 CONSERV 51 oral FTY# 51 ACCLAIM 51 TACE 51 GEM OS2 51 RG# [001] 51 adult chronic ITP 51 statistically significant 51 PSN# [002] 51 Clolar ® 51 SEROQUEL 51 Genous stent 51 varespladib 51 weekly subcutaneous injections 51 MGd 51 Wisconsin Sleep Cohort 51 sorafenib 51 evaluable subjects 51 AZILECT R 51 noninfectious uveitis 51 statistically significant reduction 51 HCV NS5B polymerase 51 Zerenex 51 PARTNER Trial 51 pharmacokinetics 51 Aptivus 51 preclinical efficacy 51 generalizability 51 Placebo Controlled 51 VFEND 51 venlafaxine XR 51 PRIMO CABG2 51 Aryplase 51 intravenously administered 51 ibandronate 51 evaluating Xcytrin 51 Mylotarg 51 CUSTOM III 51 calcium supplementation 51 AZX# 51 Efficacy 51 AERAS-#/Crucell Ad# 50 febuxostat 50 plus prednisone 50 Dapagliflozin 50 Rasilez Tekturna 50 Abciximab 50 ZD# [001] 50 cilengitide 50 cisplatin vinorelbine 50 Tavocept 50 mCRC patients 50 nitazoxanide 50 MIVI III 50 gemcitabine 50 Prospective Randomized Trial 50 dirucotide MBP# 50 direct thrombin inhibitor 50 mg/m2 cohort 50 WHIMS 50 maximally tolerated dose 50 relapsed APL 50 goserelin 50 randomized controlled trials RCTs 50 telaprevir dosing 50 lorcaserin Phase 50 administered subcutaneously 50 atherothrombotic events 50 antiplatelet agent 50 tolerated dose MTD 50 MSI #F 50 Digital Mammographic Imaging 50 Sirolimus eluting Coronary Stent 50 evaluating carfilzomib 50 FIX HF 5 50 TAXUS TM 50 Randomized Study 50 trabedersen 50 Parkinson disease levodopa induced 50 Sibutramine Cardiovascular Outcomes 50 oral sapacitabine 50 pharmacokinetic characteristics 50 Cloretazine R VNP#M 50 olaparib 50 TDF FTC 50 Women Ischemia Syndrome 50 selective androgen receptor modulator 50 MoxDuo 50 demonstrated clinically meaningful 50 Feasibility Trial 50 CR# vcMMAE 50 Zemplar Capsules 50 teriparatide 50 CRLX#

Back to home page